Search clinical trials for: Thyroid cancer, differentiated epithelial

Total 24118 results

City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
Grupo Espanol de Tumores Neuroendocrinos
Gilead Sciences; MFAR

Not yet recruiting

Sacituzumab govitEcan in THYroid Cancers (SETHY)

Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

Spain
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
Soroka University Medical Center

Recruiting

Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Cancer | Lymph Node Metastases

Israel
Children's Hospital of Philadelphia
United States Department of Defense

Recruiting

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Pediatric Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Thyroid Gland Medullary Carcinoma | Thyroid Gland Papillary Carcinoma | Malignant Thyroid Gland Neoplasm

United States
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Zhujiang Hospital

Recruiting

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Papillary Thyroid Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
SpeciCare
University of Washington; Georgia Institute of Technology; Predictive Oncology; Netnoid... and other collaborators

Recruiting

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (PIONEER)

Melanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Hepatocellular Carcinoma | Transitional Cell Carcinoma | Glioblastoma Multiforme | Cholangiocarcinoma | Small-cell Lung Cancer | Oligodendroglioma | Cancer of Head and Neck | Cancer of Liver | Cancer of Pancreas | Cancer of Brain and Nervous System | Adrenal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States
Ipsen

Completed

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

Renal Cell Carcinoma | Hepatocellular Carcinoma | Differentiated Thyroid Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...

United States
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Thyroid Gland Medullary Carcinoma | Differentiated Thyroid Gland Carcinoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
Memorial Sloan Kettering Cancer Center

Completed

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Thyroid Cancer (Follicular Cell) | BRAF V600E Mutation Positive

United States
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Thyroid Cancer | Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Thyroid Cancer, Follicular | Thyroid Cancer | Papillary Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer | Hurthle Cell Tumor | Hurthle Cell Thyroid Neoplasia

United States
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Grupo Español de Tratamiento de Tumores de Cabeza...

Active, not recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma (MOLTHY)

Differentiated Thyroid Carcinoma | Medullary Thyroid Carcinoma

Spain
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Thomas Jefferson University

Active, not recruiting

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Differentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer

United States
Hospices Civils de Lyon

Active, not recruiting

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Thyroid Cancer

France
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.

Lymph Node Metastases | Differentiated Thyroid Carcinoma | Lymph Node Dissection

China
Medstar Health Research Institute
Pfizer

Completed

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer (IIT Sutent)

Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Follicular Thyroid Cancer

United States
Tel-Aviv Sourasky Medical Center

Completed

The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience

Papillary Thyroid Cancer | Well Differentiated Thyroid Carcinoma
European Organisation for Research and Treatment...

Completed

Nintedanib(BIBF1120) in Thyroid Cancer

Differentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)

France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
University of Pennsylvania

Completed

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Metastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer

United States
Centre Leon Berard
GlaxoSmithKline

Completed

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Thyroid Carcinoma

France
University of Arizona

Completed

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Melanoma | Renal Cell Carcinoma | HCC | Hepatocellular Carcinoma | Metastatic Cancer | Metastatic Melanoma | Colon Cancer | Differentiated Thyroid Cancer | Metastatic Colon Cancer

United States
National Cancer Institute (NCI)

Terminated

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Thyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
Johns Hopkins University
M.D. Anderson Cancer Center; Genzyme, a Sanofi Company; Gustave Roussy, Cancer...

Completed

Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer

Thyroid Cancer

United States, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Novartis; National Comprehensive Cancer Network

Completed

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Cholangiocarcinoma | Soft-tissue Sarcoma | Solid Tumors | Thyroid Cancer

United States
National Cancer Institute (NCI)
Exelixis

Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditions

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Poorly Differentiated Thyroid Carcinoma

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Merkel Cell Carcinoma | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor | Functional Pancreatic Neuroendocrine Tumor | Malignant Somatostatinoma | Metastatic Adrenal Gland Pheochromocytoma | Multiple Endocrine Neoplasia Type 1 | Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia... and other conditions

Search clinical trials for: Thyroid cancer, differentiated epithelial

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations